NeuroPace

NeuroPace is a neurotechnology company headquartered in Mountain View, California, focused on developing closed-loop neuromodulation solutions for patients with drug-resistant epilepsy. The company's flagship product, the RNS System, is the first and only FDA-approved responsive neurostimulation device that continuously monitors electrical activity in the brain and automatically delivers targeted stimulation when abnormal patterns are detected. Unlike conventional neurostimulation approaches that deliver stimulation on a fixed schedule, the RNS System operates in a fully closed-loop manner, sensing and responding to the brain's activity in real time to prevent seizures before they fully manifest. This adaptive, patient-specific approach represents a fundamental shift in how neuromodulation therapy can be delivered for neurological conditions.

NeuroPace received FDA approval for the RNS System in 2013, marking a landmark regulatory milestone in the neurostimulation field, and has since built a growing commercial presence among epilepsy centers and neurology specialists across the United States. The company is publicly traded on the NASDAQ exchange under the ticker symbol NPCE, reflecting its transition from a development-stage organization to a commercial-stage medical device company. Clinical data supporting the RNS System has demonstrated sustained and durable seizure reduction over long-term follow-up periods, with outcomes continuing to improve over years of use as the device learns each patient's unique brain activity patterns. These results have strengthened NeuroPace's position within the epilepsy treatment landscape and supported broader adoption among patients who have failed multiple anti-seizure medications.

NeuroPace holds significant importance to the broader neurotech industry as a pioneer in closed-loop, brain-responsive therapy and a proof of concept that adaptive neuromodulation is both clinically viable and commercially achievable. By demonstrating that an implantable device can successfully record, interpret, and respond to neural signals in real time over extended periods, NeuroPace has helped establish the foundational framework for next-generation neurotechnology applications across a range of neurological and psychiatric conditions. The longitudinal brain activity data collected through the RNS System also represents a valuable and largely untapped resource for advancing scientific understanding of epilepsy and other brain disorders. As the neurotech field moves increasingly toward intelligent, closed-loop systems, NeuroPace's work serves as an important reference point for developers, clinicians, and investors alike.